Sort   by:  
 Page size 
ProteomicsSFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2
• Activating mutations of Shp2 cause conditions such as Noonan syndrome and juvenile myelomonocytic leukemia (JMML), with unmet therapeutic needs. • SFX-01, a sulforaphane complex, modifies cysteine residues and targets proteins including Shp2, where it induces an inhibitory modification at the acti...
ORGANISM(S): Mus musculus (Mouse) 
2025-06-12 | PXD061655 | Pride
Shp2 Sfx-01 Myeloid cell proliferation Noonan syndrome Phosphoproteomics Lc-ms/ms 
ProteomicsSFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2
Activating mutations of Src homology-2 domain-containing protein tyrosine phosphatase-2 (Shp2) cause multiple childhood conditions for which there is an unmet therapeutic need, including juvenile myelomonocytic leukemia (JMML) and Noonan syndrome. Using unbiased proteomics, the protein targets of SF...
ORGANISM(S): Mus musculus (Mouse) 
2025-06-13 | PXD061882 | Pride
Sulforaphane Homology 2 containing protein tyrosine phosphatase 2 Juvenile myelomonocytic leukemia 
UnknownSFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.
Not available
S-EPMC12340136 | biostudies-literature
UnknownA Randomised Controlled Trial of SFX-01 After Subarachnoid Haemorrhage - The SAS Study.
Not available
S-EPMC12202693 | biostudies-literature
UnknownTargeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer.
Not available
S-EPMC7299846 | biostudies-literature
UnknownAntitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcoma.
Not available
S-EPMC11229215 | biostudies-literature
UnknownStudy protocol for SFX-01 after subarachnoid haemorrhage (SAS): a multicentre randomised double-blinded, placebo controlled trial.
Not available
S-EPMC7170552 | biostudies-literature
UnknownSFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trial.
Not available
S-EPMC10926007 | biostudies-literature
UnknownA Phase 1 Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enteric-Coated Stabilized Sulforaphane (SFX-01) in Male Participants.
Not available
S-EPMC11782309 | biostudies-literature
UnknownMultiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma.
Not available
S-EPMC8626029 | biostudies-literature
Sort   by:  
 Page size